Digoxin
- Generic Name
- Digoxin
- Brand Names
- Digox, Lanoxin
- Drug Type
- Small Molecule
- Chemical Formula
- C41H64O14
- CAS Number
- 20830-75-5
- Unique Ingredient Identifier
- 73K4184T59
- Background
Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.
...
- Indication
Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.
...
- Associated Conditions
- Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure
- Associated Therapies
- -
Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 24
- Registration Number
- NCT04231435
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
A Study of JNJ-70033093 and Digoxin in Healthy Participants
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT04206488
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-10-28
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 11
- Registration Number
- NCT04141995
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04094519
- Locations
- 🇲🇩
Site MD37301, Chisinau, Moldova, Republic of
Digoxin Induced Dissolution of CTC Clusters
- Conditions
- Interventions
- First Posted Date
- 2019-04-26
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 58
- Registration Number
- NCT03928210
- Locations
- 🇨🇭
University Hospital Zurich (USZ), Zürich, Switzerland
🇨🇭Breast Cancer Center, University Hospital Basel, Basel, Switzerland
🇨🇭Kantonspital Baselland (KSBL), Liestal, Baselland, Switzerland
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-03-26
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Danae Hamouda, MD
- Target Recruit Count
- 15
- Registration Number
- NCT03889795
- Locations
- 🇺🇸
University of Toledo, Eleanor N. Dana Cancer Center, Toledo, Ohio, United States
Pharmacokinetics and Safety Profile of Digoxin in Infants With Single Ventricle Congenital Heart Disease
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Christoph P Hornik, MD MPH
- Target Recruit Count
- 50
- Registration Number
- NCT03877965
- Locations
- 🇺🇸
Nicklaus Children's Hospital, Miami, Florida, United States
🇺🇸Morgan Stanley Children's Hospital of New York Presbyterian, New York, New York, United States
🇺🇸The Children's Hospital Colorado, Aurora, Colorado, United States
Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers
- Conditions
- Interventions
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Ironwood Pharmaceuticals, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT03856970
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide
- Conditions
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 62
- Registration Number
- NCT03801759
- Locations
- 🇨🇦
inVentiv Health Clinique Inc., Québec City, Quebec, Canada
Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 982
- Registration Number
- NCT03783429
- Locations
- 🇳🇱
Gelre Ziekenhuizen, Apeldoorn, Netherlands
🇳🇱Ziekenhuis Gelderse Vallei, Ede, Netherlands
🇳🇱Groene Hart Ziekenhuis, Gouda, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.